Choose Your Country or Region

Anti-Insulin Receptor β Rabbit Antibody [C9B17]

Catalog No.: F4144

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IP1:100 IHC1:50 - 1:200 IF1:50 - 1:200 FCM1:50 - 1:200

Application
WB, IP, IHC, IF , FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
95 kDa, 220 kDa

Datasheet & SDS

Biological Description

Specificity
Anti-Insulin Receptor β Rabbit Antibody [C9B17] detects endogenous levels of total Insulin Receptor β protein.

Clone
C9B17

Synonym(s)
Insulin receptor, IR, Insulin receptor subunit alpha, Insulin receptor subunit beta, CD220, INSR

Background
Insulin receptor β (IR-β) is one of the two subunits forming the insulin receptor, a heterotetrameric protein complex consisting of two extracellular α-subunits and two transmembrane β-subunits. The β-subunit spans the cell membrane and includes an intracellular tyrosine kinase domain crucial for signal transduction. Upon insulin binding to the α-subunits, the receptor undergoes conformational changes that activate the β-subunit’s kinase domain through autophosphorylation of specific tyrosine residues. This phosphorylation event triggers downstream signaling pathways such as PI3K/Akt and MAPK, which regulate glucose transport, metabolism, cell growth, and gene expression. The β-subunit contains extracellular fibronectin type III domains (FnIII-2 and FnIII-3), a transmembrane region, and the intracellular kinase domain. The activation mechanism is a tightly controlled stepwise process involving structural changes that bring the intracellular kinase domains into proximity to facilitate trans-autophosphorylation. Regulation of IR-β involves not only tyrosine phosphorylation for activation but also serine/threonine phosphorylation, which can negatively regulate receptor activity and contribute to insulin resistance. Additionally, post-translational modifications like glycosylation affect its proper folding, trafficking, and surface expression. Abnormalities in IR-β function, such as impaired autophosphorylation or altered receptor expression, are linked to insulin resistance and the pathogenesis of type 2 diabetes and other metabolic disorders.

Background

Insulin receptor β (IR-β) is one of the two subunits forming the insulin receptor, a heterotetrameric protein complex consisting of two extracellular α-subunits and two transmembrane β-subunits. The β-subunit spans the cell membrane and includes an intracellular tyrosine kinase domain crucial for signal transduction. Upon insulin binding to the α-subunits, the receptor undergoes conformational changes that activate the β-subunit’s kinase domain through autophosphorylation of specific tyrosine residues. This phosphorylation event triggers downstream signaling pathways such as PI3K/Akt and MAPK, which regulate glucose transport, metabolism, cell growth, and gene expression. The β-subunit contains extracellular fibronectin type III domains (FnIII-2 and FnIII-3), a transmembrane region, and the intracellular kinase domain. The activation mechanism is a tightly controlled stepwise process involving structural changes that bring the intracellular kinase domains into proximity to facilitate trans-autophosphorylation. Regulation of IR-β involves not only tyrosine phosphorylation for activation but also serine/threonine phosphorylation, which can negatively regulate receptor activity and contribute to insulin resistance. Additionally, post-translational modifications like glycosylation affect its proper folding, trafficking, and surface expression. Abnormalities in IR-β function, such as impaired autophosphorylation or altered receptor expression, are linked to insulin resistance and the pathogenesis of type 2 diabetes and other metabolic disorders.

References
https://pubmed.ncbi.nlm.nih.gov/2986534/ https://pubmed.ncbi.nlm.nih.gov/37779149/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%